Date: 2012-02-29
Type of information: Production agreement
Compound: live bacteria
Company: Cobra Biologics (UK) undisclosed clinical stage biotechnology company
Therapeutic area: Genetic diseases - Rare diseases - Metabolic diseases
Type agreement: production
manufacturing
Action mechanism:
Disease: undisclosed rare genetic disease
Details: Cobra Biologics, the international clinical and commercial manufacturer of biologics and pharmaceuticals, has signed an agreement with a clinical stage biotechnology company to produce a drug substance under cGMP. The product, consisting of live bacteria, will be used for toxicology and clinical studies for treatment of a metabolic disorder. The disorder is a rare genetic disease leading to kidney failure and end stage renal disease. The newly aquired Cobra facility in Matfors, Sweden, has a long standing experience in large scale microbial production and will perform both the upstream and downstream work to isolate and purify the live bacteria.
Financial terms:
Latest news:
